1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO, M0
Zasocitinib IR Event Phase 3 Psoriasis Data Presented at AAD March 28th, 2026 ET / March 29th, 2026 JST
Announces Candidates for Board of Directors and Change in Representative Director at Upcoming Shareholders Meeting
Announces Next Steps in Its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook
Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Earnings Report for the Nine-month Period Ended December 31, 2025
Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
Protagonist Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
Annual and Transition Report of Foreign Private Issuers
Prospectus Filed Pursuant to Rule 424(b)(2)
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Registration of Securities
No filings found
Initial Statement of Beneficial Ownership
Free Writing Prospectus
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Specialized Disclosure Report